A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Do, Hongdo ^a,b,d   Wong, Nicholas C ^b,d   Murone, Carmel ^b   John, Thomas ^c   Solomon, Benjamin ^a,d   Mitchell, Paul L ^c   Dobrovic, Alexander ^a,b,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^c AUSTIN HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TUMOR PROTEIN;

ARTICLE; DNA METHYLATION; DNA REPAIR; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PROMOTER REGION; TUMOR CELL CULTURE;

CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; DNA REPAIR; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; TUMOR CELLS, CULTURED;

EID: 84894768842     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04186     Document Type: Article

References (60)

1. Taron, M. et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13, 2443-9 (2004).
2. Rosell, R. et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 4, e5133 (2009).
3. Papadaki, C. et al. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol 7, 663-71 (2012).
4. Papadaki, C. et al. Correlation of BRCA1, TXR1 and TSP1mRNAexpression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer 104, 316-23 (2011).
5. Boukovinas, I. et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non- small-cell lung cancer patients. PLoS One 3, e3695 (2008).
6. Rosell, R. et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2, e1129 (2007).
7. Font, A. et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatinbased chemotherapy in bladder cancer. Ann Oncol 22, 139-44 (2011).
8. Weberpals, J. et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 124, 806-15 (2009).
9. Dabholkar, M. et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84, 1512-7 (1992).
10. Middleton, M. R. & Margison, G. P. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 4, 37-44 (2003). (Pubitemid 36124189)
11. Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343, 1350-4 (2000).
12. Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8, 193-204 (2008). (Pubitemid 351301852)
13. Mikeska, T., Bock, C., Do, H. & Dobrovic, A. DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn 12, 473-87 (2012).
14. Curtin, N. J. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 12, 801-17 (2012).
15. Mikeska, T.,Candiloro, I.&Dobrovic, A. The implications of heterogeneousDNA methylation for the accurate quantification of methylation. Epigenomics 2, 561-573 (2010).
16. Cottrell, S. E. & Laird, P. W. Sensitive detection of DNA methylation. Ann N Y Acad Sci 983, 120-30 (2003). (Pubitemid 36399325)
17. Brandes, J. C., Carraway, H. & Herman, J. G. Optimal primer design using the novel primer design program:MSPprimer provides accurate methylation analysis of the ATM promoter. Oncogene 26, 6229-37 (2007). (Pubitemid 47414370)
18. Wojdacz, T. K. & Dobrovic, A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 35, e41 (2007).
19. Lord, R. V. et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8, 2286-91 (2002). (Pubitemid 34753602)
20. Huang, K. T. et al. DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Breast Cancer Res Treat 124, 555-65 (2010).
21. Wong, E. M. et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early- onset breast cancer. Cancer Prev Res (Phila) 4, 23-33 (2011).
22. Mikeska, T., Carney, D. A., Seymour, J. F. & Dobrovic, A. No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia. Leuk Lymphoma 53, 1420-2 (2012).
23. Wu, Y. H. et al. Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers. Oncogene 26, 4761-73 (2007).
24. Chaisaingmongkol, J. et al. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma. Oncogene 31, 5108-16 (2012).
25. Chen, H. Y., Shao, C. J., Chen, F. R., Kwan, A. L. & Chen, Z. P. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer 126, 1944-54 (2010).
26. Peng, B. et al. Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells. J Biol Chem 280, 4182-7 (2005).
27. Virmani, A. K. et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 7, 1998-2004 (2001). (Pubitemid 32994838)
28. Brock, M. V. et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358, 1118-28 (2008). (Pubitemid 351398486)
29. Vaissiere, T. et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res 69, 243-52 (2009).
30. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003 (2005). (Pubitemid 40349502)
31. Hegi, M. E., Sciuscio, D., Murat, A., Levivier, M. & Stupp, R. Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res 15, 5026-31 (2009).
32. Tomii, K. et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer 120, 566-73 (2007). (Pubitemid 44969028)
33. Das, P. M. et al. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol Cancer 5, 28 (2006).
34. Enokida, H. et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer 116, 174-81 (2005). (Pubitemid 40967252)
35. Herman, J. G.,Graff, J. R.,Myohanen, S., Nelkin, B.D.&Baylin, S. B. Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93, 9821-6 (1996).
36. Chiang, J. W., Karlan, B. Y., Cass, L. & Baldwin, R. L. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 101, 403-10 (2006). (Pubitemid 43729975)
37. Dobrovic, A. & Simpfendorfer, D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57, 3347-50 (1997). (Pubitemid 27355472)
38. Marsit, C. J. et al. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23, 1000-4 (2004).
39. Lee, M. N. et al. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 13, 832-8 (2007).
40. van Dijk, J. P. et al. A novel, essential control for clonality analysis with human androgen receptor gene polymerase chain reaction. Am J Pathol 161, 807-12 (2002). (Pubitemid 34988367)
41. Kupper, D., Reuter, M.,Meisel, A.&Kruger, D. H. Reliable detection ofDNACpG methylation profiles by the isoschizomers MspI/HpaII using oligonucleotide stimulators. Biotechniques 23, 843-7 (1997). (Pubitemid 27476136)
42. Nouspikel, T. DNA repair in mammalian cells: Nucleotide excision repair: variations on versatility. Cell Mol Life Sci 66, 994-1009 (2009).
43. Khan, O. et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitorbased therapy. Proc Natl Acad Sci U S A 107, 6532-7 (2010).
44. Miyanaga, A. et al. Antitumor activity of histone deacetylase inhibitors in nonsmall cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 7, 1923-30 (2008).
45. Bandaru, V., Sunkara, S., Wallace, S. S. & Bond, J. P. A novel human DNA glycosylase that removes oxidative DNA damage and is homologous to Escherichia coli endonuclease VIII. DNA Repair (Amst) 1, 517-29 (2002). (Pubitemid 34655710)
46. Rosenquist, T. A. et al. The novel DNA glycosylase, NEIL1, protects mammalian cells from radiation-mediated cell death. DNA Repair (Amst) 2, 581-91 (2003). (Pubitemid 36507126)
47. Virmani, A. K. et al. Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol Biomarkers Prev 11, 291-7 (2002). (Pubitemid 34327008)
48. Cancer Genome Atlas Research, N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-25 (2012).
49. Bibikova, M. et al. Genome-wide DNA methylation profiling using Infinium(R) assay. Epigenomics 1, 177-200 (2009).
50. Safar, A. M. et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 11, 4400-5 (2005).
51. Safar, A. M. et al. Promoter hypermethylation for molecular nodal staging in nonsmall cell lung cancer. Arch Pathol Lab Med 131, 936-41 (2007). (Pubitemid 46906386)
52. Wang, Y. et al.Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 112, 1325-36 (2008). (Pubitemid 351429748)
53. Wu, J. Y. et al. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status. Ann Surg Oncol 15, 3272-7 (2008).
54. Feng, Q. et al. DNA methylation in tumor and matched normal tissues from nonsmall cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 17, 645-54 (2008). (Pubitemid 351469215)
55. Liu, Y., Lan, Q., Siegfried, J. M., Luketich, J. D. & Keohavong, P. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 8, 46-51 (2006).
56. Kim, Y. T. et al. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg 130, 1378 (2005).
57. Tang, M., Torres-Lanzas, J., Lopez-Rios, F., Esteller, M. & Sanchez-Cespedes, M. Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung. Int J Cancer 119, 2603-6 (2006).
58. Seng, T. J. et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 99, 375-82 (2008).
59. Wang, Y. C. et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 111, 887-95 (2003).
60. Geng, X., Wang, F., Zhang, L. & Zhang, W. M. Loss of heterozygosity combined with promoter hypermethylation, the main mechanism of human MutL Homolog (hMLH1) gene inactivation in non-small cell lung cancer in a Chinese population. Tumori 95, 488-94 (2009).